ArticleJournal for immunotherapy of cancer2025

Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.

Bi-Cheng WangPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.